Cross-elbow stent placement for refractory arteriovenous fistula stenosis and chronic total occlusion in hemodialysis patients: a single-center retrospective cohort of 42 cases
- 1Department of Nephrology, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China
Abstract
Cross-elbow stent placement in hemodialysis arteriovenous fistulas (AVFs) has been avoided due to risks of fracture, kinking, deformation, migration, and infection. However, elbow lesions may be refractory to angioplasty and progress to chronic total occlusion (CTO). We evaluated the safety, feasibility, and patency of cross-elbow stenting for AVF salvage. Consecutive adult hemodialysis patients who received cross-elbow stents for clinically significant AVF stenosis or CTO (September 2021 – March 2026) at a single center were retrospectively analyzed. Primary outcomes were target lesion primary patency (TLPP), access circuit primary patency (ACPP), access circuit secondary patency, and access circuit assisted primary patency, estimated by Kaplan–Meier. Technical and clinical success and complications were recorded. Forty-two patients were included; 45.2% had CTO and 57.1% had prior PTA. Eluvia-based stents were used in 83.3%. Technical and clinical success were both 100%. Mean access flow increased from 407 ± 267 to 839 ± 188 mL/min. TLPP at 3, 6, 12, and 24 months was 90.1%, 84.4%, 76.9%, and 76.9%, respectively. No stent fracture, migration, kinking, or infection occurred. Cross-elbow stenting was technically feasible and provided favorable short- to mid-term patency without device-related complications, supporting its use as a salvage option for selected refractory AVF lesions and CTOs.
Related
- Comparative outcomes of arteriovenous accesses with and without tunneled hemodialysis catheters: A retrospective cohort study.
- Progress on the related mechanisms of vascular calcification in autogenous arteriovenous fistula in hemodialysis patients
- Ultrasound-guided angioplasty of arteriovenous fistula for hemodialysis: initial experience of a single center
- Current status of pharmacological interventions for preventing stenosis of arteriovenous hemodialysis access
- Exploratory Transcriptomic Profiling of Vein Tissue from Diabetic Patients Undergoing Arteriovenous Fistula Creation for Hemodialysis
BibTeX
@article{huang2026crosselbow,
title = {{Cross-elbow stent placement for refractory arteriovenous fistula stenosis and chronic total occlusion in hemodialysis patients: a single-center retrospective cohort of 42 cases}},
author = {Yibiao Huang and Linnan Bai and Junnan Wu and Xuan Zheng and Mingxi Lu},
journal = {Renal Failure},
year = {2026},
month = oct,
doi = {10.1080/0886022x.2026.2738994},
url = {https://doi.org/10.1080/0886022x.2026.2738994},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Cross-elbow stent placement for refractory arteriovenous fistula stenosis and chronic total occlusion in hemodialysis patients: a single-center retrospective cohort of 42 cases
AU - Yibiao Huang
AU - Linnan Bai
AU - Junnan Wu
AU - Xuan Zheng
AU - Mingxi Lu
PY - 2026
DA - 2026/10/27
JO - Renal Failure
DO - 10.1080/0886022x.2026.2738994
UR - https://doi.org/10.1080/0886022x.2026.2738994
AB - Cross-elbow stent placement in hemodialysis arteriovenous fistulas (AVFs) has been avoided due to risks of fracture, kinking, deformation, migration, and infection. However, elbow lesions may be refractory to angioplasty and progress to chronic total occlusion (CTO). We evaluated the safety, feasibility, and patency of cross-elbow stenting for AVF salvage. Consecutive adult hemodialysis patients who received cross-elbow stents for clinically significant AVF stenosis or CTO (September 2021 – March 2026) at a single center were retrospectively analyzed. Primary outcomes were target lesion primary patency (TLPP), access circuit primary patency (ACPP), access circuit secondary patency, and access circuit assisted primary patency, estimated by Kaplan–Meier. Technical and clinical success and complications were recorded. Forty-two patients were included; 45.2% had CTO and 57.1% had prior PTA. Eluvia-based stents were used in 83.3%. Technical and clinical success were both 100%. Mean access flow increased from 407 ± 267 to 839 ± 188 mL/min. TLPP at 3, 6, 12, and 24 months was 90.1%, 84.4%, 76.9%, and 76.9%, respectively. No stent fracture, migration, kinking, or infection occurred. Cross-elbow stenting was technically feasible and provided favorable short- to mid-term patency without device-related complications, supporting its use as a salvage option for selected refractory AVF lesions and CTOs.
SN - 0886-022X
SN - 1525-6049
ER -